Study #2024-0196
Phase I/II study of engineered T cell receptor-modified NK cells targeting PRAME in conjunction with lymphodepleting chemotherapy for the management of relapse/refractory myeloid malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine phosphate, Decitabine, Dexamethasone
Description
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphodepleting Chemotherapy, Myeloid Malignancies
Study phase:
Physician name:
Jeremy Ramdial
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.